Comment

  • 7 December 2016

    Inclisiran offers hope for dyslipidemia patients

    Therapy inclisiran (formerly ALN-PCSsc) is currently being developed by The Medicines Company and Alnylam Pharmaceuticals. It specifically targets the PCSK9 messenger ribonucleic acid (mRNA), inhibiting protein synthesis.